Pimavanserin for the treatment of Parkinson's disease psychosis

@article{Friedman2013PimavanserinFT,
  title={Pimavanserin for the treatment of Parkinson's disease psychosis},
  author={Joseph H. Friedman},
  journal={Expert Opinion on Pharmacotherapy},
  year={2013},
  volume={14},
  pages={1969 - 1975}
}
  • J. Friedman
  • Published 10 September 2013
  • Medicine
  • Expert Opinion on Pharmacotherapy
Introduction: Parkinson's disease (PD) is a neurobehavioral disorder defined by its motor features. Its treatment is frequently complicated by the presence of psychotic symptoms, most prominently hallucinations and delusions. These cause major distress and are the primary cause for nursing home placement. Current treatment requires either a reduction in medications for mobility or the addition of atypical antipsychotics, none of which are approved in the United States, and which are associated… 
View on Taylor & Francis
ncbi.nlm.nih.gov
12 Citations
Background Citations
1

12 Citations

Citation Type

Citation Type

Pimavanserin for Psychotic Symptoms in People With Parkinsonism: A Second Chart Review
TLDR
Almost 50% of parkinsonian patients with psychotic symptoms found Pim to be a useful medication, which they continue to take, according to a chart review of all patients started on the drugs since the one earlier report.
Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson's disease and dementia with Lewy bodies.
TLDR
Accounting for efficacy, safety and tolerability, pimavanserin may be more clinically useful for promptly managing psychosis, while quetiapine may confer additional secondary benefits long-term.
A Novel Synthesis of Pimavanserin: A Selective Serotonin 5-HT2A Receptor Inverse Agonist
Psychosis in patients with Parkinson’s disease (PD) is a common, at times debilitating, condition and represents a major unmet need in the treatment of PD. Pimavanserin…
Targeting Serotonin 5-HT2A Receptors to Better Treat Schizophrenia: Rationale and Current Approaches
TLDR
The evidence for the role of the serotonin type 2A receptor (5-HT2AR) in schizophrenia is assessed and Food and Drug Administration (FDA)-approved and investigational 5- HT2AR-modulating compounds are reviewed.
Antipsychotic drugs and sudden cardiac death: A literature review of the challenges in the prediction, management, and future steps
TLDR
Recent advances in understanding the link between SCD and antipsychotic drug usage, as well as in utilizing wearable medical devices for monitoring of cardiac arrhythmias are summarized.
(11)C-labeling and preliminary evaluation of pimavanserin as a 5-HT2A receptor PET-radioligand.
TLDR
The lack of displacement by the 5-HT2R antagonist and binding in the thalamus suggests that [(11)C]pimavanserin is not selective for the 5,HT2AR in pigs.
PET Imaging of the 5-HT 2A Receptor System: A Tool to Study the Receptor’s In Vivo Brain Function
TLDR
The serotonergic 5-HT2A receptor system plays a key modulatory role for many brain functions such as regulation of mood, temperature, sex, appetite and emotions and makes it an obvious target for many drugs.
Investigation of metabolic profile of pimavanserin in rats by ultrahigh-performance liquid chromatography combined with Fourier transform ion cyclotron resonance mass spectrometry.
TLDR
This report presents the first study of screening and identification of the metabolites of pimavanserin, a promising candidate for treating Parkinson's disease psychosis, using the UHPLC/FT-ICR-MS method, a powerful tool for exploring and identifying metabolites in complex biological samples.
5-HT2 receptor affinity, docking studies and pharmacological evaluation of a series of 1,3-disubstituted thiourea derivatives.
TLDR
Molecular docking studies using a homology model of 5-HT2A revealed a significant role of hydrogen bonds between both thiourea NH groups and Asp155/Tyr370 residues, as well as π-π interaction with Phe339.
Quantification of Pimavanserin in Bulk and Tablet Dosage Form Using A Stability Indicating High Performance Liquid Chromatographic Method
Background: Pimavanserin, an antipsychotic agent, is used to treat patients suffering with Parkinson's disease. Till now no stability indicating reverse phase HPLC method was reported for the…
...
1
2
...

References

SHOWING 1-10 OF 50 REFERENCES
Aripiprazole associated with severe exacerbation of Parkinson's disease
TLDR
Aripiprazole is a novel atypical antipsychotic with an apparently unique mechanism of action—a dopamine system stabilizer with partial agonist effect at D2 and 5HT1a receptors that would treat psychotic symptoms in Parkinson’s disease with fewer extrapyramidal side effects.
Parkinson Disease Psychosis: Update
  • J. Friedman
  • Psychology, Medicine
    Behavioural neurology
  • 2013
TLDR
Only clozapine has level A evidence to support its use in PD patients with psychosis (PDP), whether demented or not, and other antipsychotic drugs have been reported to worsen motor function and data on the effectiveness of cholinesterase inhibitors is limited.
Parkinson's disease: The quintessential neuropsychiatric disorder
  • D. Weintraub, D. Burn
  • Psychology, Medicine
    Movement disorders : official journal of the Movement Disorder Society
  • 2011
TLDR
The emergent focus on nonmotor aspects of Parkinson's disease over the past quarter of a century is highlighted by a nonlinear increase in the number of articles published devoted to this topic.
Pimavanserin, a Serotonin2A Receptor Inverse Agonist, for the Treatment of Parkinson's Disease Psychosis
TLDR
Pimavanserin showed significantly greater improvement in psychosis in patients with PDP at a dose which did not impair motor function, or cause sedation or hypotension, which support the hypothesis that attenuation of psychosis secondary to DA receptor stimulation in PDP may be achieved through selective 5-HT2A receptor antagonism.
Epidemiology of psychosis in Parkinson's disease
TLDR
It is suggested that hallucinations persist and worsen in individual patients, and that their prevalence increases with time, and there is no simple dose-effect relationship between dopaminergic treatment and the presence or severity of hallucinations.
Diagnostic criteria for psychosis in Parkinson's disease: Report of an NINDS, NIMH work group
  • B. Ravina, K. Marder, +15 authors C. Goetz
  • Psychology, Medicine
    Movement disorders : official journal of the Movement Disorder Society
  • 2007
TLDR
It is suggested that PDPsy may result from progression of the disease process underlying PD, rather than a comorbid psychiatric disorder or drug intoxication, and are a potential indication for therapy development.
Psychiatric syndromes in Parkinson's disease
TLDR
Standardized criteria should be used to diagnose depression and apathy in Parkinson's disease and psychotherapy and pharmacotherapy are useful treatment modalities for affective disorders in Parkinson’s disease.
Drug-Induced Psychosis in Parkinson Disease: Phenomenology and Correlations Among Psychosis Rating Instruments
TLDR
Nonvisual hallucinations and delusions may occur more frequently in DIP than previously thought and these symptoms, plus agitation and hostility, may ultimately be the best measure of DIP in patients with PD.
Aripiprazole for Drug-Induced Psychosis in Parkinson Disease: Preliminary Experience
TLDR
The preliminary experience in 8 patients with probable Parkinson disease treated with aripiprazole for drug-induced psychosis is mixed but not very encouraging, and controlled studies are needed to evaluate aripIPrazole in parkinsonian patients.
Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease
TLDR
Pimavanserin, a selective 5- HT2A antagonist/inverse agonist, reversed the psychotic-like behavioral deficits, suggesting that nigrostriatal (6-hydroxydopamine) lesions induced alterations in 5-HT2A-mediated signaling.
...
1
2
3
4
5
...